AbbVie Reports Second-Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
July 31, 2026 7:49 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $3.65, $0.06 worse than the analyst estimate of $3.71. Revenue for the quarter came in at $16.99 billion versus the consensus estimate of $16.77 billion.
GUIDANCE:
AbbVie sees FY2026 EPS of $13.87-$14.07, versus the consensus of $14.12.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More